Clinical trials: Advanced Gastrointestinal Tumors
Locally Advanced Pancreatic Adenocarcinoma
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
- Trial name
- NCT03077685
- Testing
- NanoPac®
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- NanOlogy, LLC
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Gastric Cancer
A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer
The main purpose of this study is to evaluate the effectiveness of LY2875358 in participants with MET diagnostic positive (+), advanced gastric or gastroesophageal junction (GEJ) cancer.
- Trial name
- NCT01874938
- Testing
- LY2875358
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumors, Triple Negative Breast Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT03797326
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 88 sites in United States, Argentina and 15 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer, Advanced Adenocarcinoma
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
According to data from Global Cancer Statistics 2018, colorectal cancer (CRC) ranks second in incidence and fifth in mortality among all cancers in China.
- Conditions
- Colorectal Cancer, Advanced Adenocarcinoma, Hyperplastic Polyp, Colorectal Neoplasms
- Trial name
- NCT04722055
- Testing
- Multigene Methylation Detection Kit
- Where
- China
- Volunteers
- 1,273 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Advanced Hepatocellular Carcinoma
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.
- Trial name
- NCT05628545
- Testing
- GDKM-100 injection
- Where
- China
- Sponsor
- Guangdong GD Kongming Biotech LLC
Advanced Gastrointestinal Stromal Tumor
Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors
The purpose of the study is to evaluate the safety and efficacy of AMG 706 in patients with gastrointestinal stromal tumor that have not been controlled while taking imatinib mesylate.
- Trial name
- NCT00254267
- Testing
- AMG 706
- Volunteers
- 35 people
- Sponsor
- Amgen
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Breast Cancer, Pancreas Cancer
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
- Conditions
- Breast Cancer, Pancreas Cancer, Prostate Cancer, Lung Cancer
- Trial name
- NCT03199586
- Testing
- NP-G2-044
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Novita Pharmaceuticals, Inc.
Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
The purpose of the dose escalation part of this study is to determine the feasibility of using the combination of copanlisib and nivolumab in subjects with advanced solid tumors, and to determine the maximum tolerated dose of…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03735628
- Testing
- Copanlisib, Nivolumab
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Bayer
Breast Cancer, Gastric Cancer
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases. The primary objective of Phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05678205
- Testing
- AB-201, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States, South Korea
- Sponsor
- Artiva Biotherapeutics, Inc.
Advanced Cancer
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
- Trial name
- NCT04148937
- Testing
- LY3475070, Pembrolizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior…
- Trial name
- AVATAR (NCT00887822)
- Testing
- Bevacizumab, Capecitabine, Cisplatin
- Where
- 14 sites in China
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche
GIST With D842V Mutated PDGFRA Gene
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in…
- Trial name
- NCT02847429
- Testing
- Crenolanib
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 120 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Advanced Solid Tumor, Gynecologic Cancer
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04682431
- Testing
- PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3
- Where
- 17 sites in United States
- Volunteers
- 127 people
- Sponsor
- Ikena Oncology
Hepatocellular Carcinoma
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma…
- Trial name
- CheckMate 9DW (NCT04039607)
- Testing
- Nivolumab, Ipilimumab, Sorafenib
- Where
- 210 sites in United States, Argentina and 24 more
- Volunteers
- 732 people
- Sponsor
- Bristol-Myers Squibb
Advanced MTAP-null Solid Tumors
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with…
- Trial name
- MTAPESTRY 101 (NCT05094336)
- Testing
- Anvumetostat, Docetaxel, Comparator Anvumetostat Test Tablet
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 329 people
- Sponsor
- Amgen
Esophageal Cancer
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent…
- Trial name
- NCT05191667
- Testing
- AN0025
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Liver Neoplasms
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).
- Trial name
- NCT00051532
- Testing
- Seocalcitol
- Where
- 5 sites in Canada, France and 3 more
- Volunteers
- 700 people
- Sponsor
- LEO Pharma
Hepatocellular Carcinoma (HCC)
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the efficacy and safety of HLX10 + HLX04 vs Sorafenibas as the First-line Treatment in Patients with Locally Advanced or Metastatic HCC…
- Trial name
- NCT04465734
- Testing
- HLX10, HLX04, Sorafenib
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.